Pacritinib for relapsed or resistant T-cell blood cancers
Treatments studied
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This Phase 2 trial studies pacritinib, an oral medicine, for T-cell lymphoma/leukemia that has come back or did not respond to prior treatment. It aims to see how well pacritinib can control the cancer and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You can sign consent forms (including permission to access your health information).
- Your heart and other body organ tests are within the study’s limits, and your performance status is 0–2.
- You have a confirmed diagnosis of a specific type of T-cell lymphoma or related condition (PTCL/CTCL) and it has relapsed or is refractory.
- You must have enough usable prior tissue samples from a recent procedure, or you may need a new biopsy if that tissue isn’t available.
- You must be able to take pills by mouth (no crushing, dissolving, or chewing).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of two targeted drugs (pacritinib plus a BTK inhibitor like ibrutinib) for people with mantle cell lymphoma that has come back or stopped responding to treatment. It may help if your current BTK inhibitor is no longer working well.
This trial tests a combination of belinostat (a targeted drug) plus either azacitidine or pralatrexate for people with relapsed or refractory T-cell lymphoma. The goal is to find a new treatment option when previous therapies have stopped working.
This trial tests a pill called pacritinib for people with Waldenström macroglobulinemia that has come back or stopped responding to other treatments. The goal is to see if pacritinib can help control the disease by blocking certain proteins that cancer cells need to grow.
This trial tests a drug called pacritinib for men with metastatic prostate cancer that has stopped responding to hormone therapies. It aims to see if blocking the JAK2/STAT5 pathway can slow cancer growth.
This trial tests adding pacritinib to standard hypomethylating agents (azacitidine or decitabine) before a stem cell transplant for people with myeloproliferative neoplasms (MPN) that have progressed to a more advanced phase.
This trial tests a drug called pacritinib for people with CMML. It's for those who haven't had JAK inhibitor therapy before and may have had only one cycle of other treatments.
Hear when a new Lymphoproliferative Disorders trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.